吡咯替尼、多西他赛和曲妥珠单抗联合治疗HER2阳性晚期乳腺癌的临床效果及安全性评价  

Clinical efficacy and safety evaluation of the combination of pyrrolitinib,docetaxel and trastuzumab for HER2-positive advanced breast cancer

作　　者：刘译婷 孙立柱 汤青 李伟 刘田田 LIU Yiting;SUN Lizhu;TANG Qing;LI Wei;LIU Tiantian(Department of Oncology,Shuyang Hospital,Jiangsu,Shuyang 223600,China)

机构地区：[1]沭阳医院肿瘤科,江苏沭阳223600

出　　处：《中国医药科学》2025年第5期124-127,共4页China Medicine And Pharmacy

基　　金：江苏省卫生健康委科研项目(M2021096)。

摘　　要：目的探究人表皮生长因子受体-2(HER2)阳性晚期乳腺癌治疗时联合采用吡咯替尼、多西他赛、曲妥珠单抗的效果。方法回顾性分析2020年5月至2024年5月的HER2阳性晚期乳腺癌患者,总计56例。以治疗方案不同分组,多西他赛+曲妥珠单抗治疗的对照组28例,吡咯替尼+多西他赛+曲妥珠单抗治疗的观察组28例。比较近期临床疗效、肿瘤标志物、炎症因子和不良反应。结果经过治疗,观察组的客观缓解率与疾病控制率高于对照组,差异有统计学意义(P<0.05);两组治疗后肿瘤标志物均降低,观察组的肿瘤标志物指标低于对照组,差异有统计学意义(P<0.05);观察组的炎症因子指标在治疗后低于对照组,差异有统计学意义(P<0.05);两组间的不良反应差异无统计学意义(P>0.05)。结论吡咯替尼、多西他赛和曲妥珠单抗联合治疗HER2阳性晚期乳腺癌具有较好的临床治疗效果,可有效降低肿瘤标志物和炎症指标,安全性良好。Objective To investigate the effect of the combination of pivotalinib,docetaxel,and trastuzumab in the treatment of human epidermal growth factor receptor-2(HER2)positive advanced breast cancer.Methods A total of 56 patients with HER2-positive advanced breast cancer from May 2020 to May 2024 were retrospectively analyzed.There were 28 cases in the control group treated with docetaxel+trastuzumab and 28 cases in the observation group treated with pyrrotinib+docetaxel+trastuzumab.Short-term clinical efficacy,tumor markers,inflammatory factors and adverse reactions were compared.Results After treatment,the objective remission rate and disease control rate of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).Tumor markers in both groups were decreased after treatment,and tumor markers in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).The inflammatory factors in the observation group were lower than those in the control group after treatment,and the difference was statistically significant(P<0.05).There was no statistical significance in adverse reactions between the two groups(P>0.05).Conclusion The combination of pyrrotinib,docetaxel and trastuzumab in the treatment of HER2-positive advanced breast cancer has good clinical efficacy,can effectively reduce tumor markers and inflammatory indicator s,and has good safety.

关 键 词：HER2阳性晚期乳腺癌 吡咯替尼 多西他赛 曲妥珠单抗 临床治疗效果 安全性 

分 类 号：R737.9[医药卫生—肿瘤]